Analyst Ratings For Apollo Endosurgery Inc (NASDAQ:APEN)
Today, Roth Capital reiterated its Buy rating on Apollo Endosurgery Inc (NASDAQ:APEN) with a price target of $9.50.
There are 0 sell ratings, 1 hold ratings, 3 buy ratings, 0 strong buy ratings on the stock.
The current consensus rating on Apollo Endosurgery Inc (NASDAQ:APEN) is Buy with a consensus target price of $10.1250 per share, a potential 25.93% upside.
Some recent analyst ratings include
- 7/17/2018-Roth Capital Reiterated Rating of Buy .
- 4/13/2018-Piper Jaffray Companies initiated coverage with a Overweight rating.
- 2/8/2018-Northland Securities Reiterated Rating of Buy.
- 7/24/2017-Craig Hallum initiated coverage with a Buy rating.
Recent Insider Trading Activity For Apollo Endosurgery Inc (NASDAQ:APEN)
Apollo Endosurgery Inc (NASDAQ:APEN) has insider ownership of 52.80% and institutional ownership of 32.77%.
- On 6/20/2018 Matthew S Crawford, Director, bought 363,500 with an average share price of $5.50 per share and the total transaction amounting to $1,999,250.00.
- On 6/20/2018 Stefanie L. Cavanaugh, CFO, bought 4,545 with an average share price of $5.50 per share and the total transaction amounting to $24,997.50.
- On 6/20/2018 Todd Newton, CEO, bought 72,727 with an average share price of $5.50 per share and the total transaction amounting to $399,998.50.
- On 3/9/2018 Matthew S Crawford, Director, bought 4,038 with an average share price of $6.20 per share and the total transaction amounting to $25,035.60.
- On 1/3/2018 Stonepine Capital, L.P., Major Shareholder, bought 22,845 with an average share price of $5.71 per share and the total transaction amounting to $130,444.95.
- On 12/29/2017 Stonepine Capital, L.P., Major Shareholder, bought 5,163 with an average share price of $5.56 per share and the total transaction amounting to $28,706.28.
- On 12/26/2017 Stonepine Capital, L.P., Major Shareholder, bought 5,287 with an average share price of $5.00 per share and the total transaction amounting to $26,435.00.
About Apollo Endosurgery Inc (NASDAQ:APEN)
Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices for the treatment of obesity. The company offers endo-bariatric products, such as Orbera intragastric balloon system and Orbera365 Managed Weight Loss System, which are non-surgical alternatives for the treatment of overweight and obese adults; and OverStitch endoscopic suturing system that enables endoscopic procedures by allowing physicians to place full-thickness sutures and secure the approximation of tissue through flexible endoscope. It also provides surgical products, including Lap-Band system, a system designed to provide minimally invasive long-term treatment of obesity; and accessories used in laparoscopic bariatric surgeries. The company sells its products primarily in the United States, Europe, Australia, Brazil, and Canada. Apollo Endosurgery, Inc. was founded in 2005 and is headquartered in Austin, Texas.
Recent Trading Activity for Apollo Endosurgery Inc (NASDAQ:APEN)
Shares of Apollo Endosurgery Inc closed the previous trading session at 8.03 −0.40 4.74% with 7.66 shares trading hands.